Azitra Expands Eligibility For Ongoing Phase 1/2 Clinical Trial Of ATR04-484 To Include Individuals With Rash Associated With KRAS And MEK Inhibitors

Loading news article.

Azitra Expands Eligibility For Ongoing Phase 1/2 Clinical Trial Of ATR04-484 To Include Individuals With Rash Associated With KRAS And MEK Inhibitors | WAPE

Azitra Expands Eligibility For Ongoing Phase 1/2 Clinical Trial Of ATR04-484 To Include Individuals With Rash Associated With KRAS And MEK Inhibitors

Article summary

Related companies

Analyzed by WAPE AI.

Comments —